RYTM — Rhythm Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $3.02bn
- $2.93bn
- $77.43m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -141 | -134 | -69.6 | -181 | -185 |
Depreciation | |||||
Non-Cash Items | 12.1 | 17.2 | -79.4 | 25.7 | 42 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 5.07 | -5.89 | 1.9 | -19.7 | 4.81 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -123 | -122 | -146 | -173 | -136 |
Capital Expenditures | -3.38 | -0.214 | -0.434 | -0.281 | -0.047 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -24.6 | 159 | -61.7 | 28.3 | -5.62 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -28 | 159 | -62.2 | 28 | -5.67 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 163 | 2.01 | 166 | 214 | 74.4 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 12.8 | 38.6 | -41.7 | 68.4 | -67.6 |